Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften E-learning Web-tv Video Audio
Tips voor Mijn BSL
UITGEBREID ZOEKEN
Inloggen
Top
Quality of Life Research
Gepubliceerd in: Quality of Life Research 1/2012

01-02-2012

Circulating levels of a biomarker of collagen metabolism are associated with health-related quality of life in patients with chronic heart failure

Auteurs: Sofia V. Chatzikyriakou, Dimitrios N. Tziakas, Georgios K. Chalikias, Dimitrios Stakos, Dimitrios Papazoglou, Asimina Lantzouraki, Adina Thomaidi, Harisios Boudoulas, Stavros Konstantinides

Gepubliceerd in: Quality of Life Research | Uitgave 1/2012

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Abstract

Purpose

Assessment of circulating levels of collagen-derived peptides has been proposed as a useful tool to monitor indirectly myocardial collagen metabolism in chronic heart failure (CHF) patients. The potential link between circulating concentrations of collagen metabolism biomarkers and health-related quality of life (HRQOL) has not been adequately evaluated. With the present study, we investigated the association between serum levels of collagen-derived peptides and HRQOL.

Methods

We studied 280 consecutive outpatients (of mean age 67 ± 10 years, 180 men) with CHF. Serum concentrations of carboxy-terminal telopeptide of collagen type I (CITP)—a marker of collagen type I degradation—were measured in all patients both at baseline and during a period of 6 months follow-up. HRQOL was assessed by Minnesota living with heart failure questionnaire (MLHFQ).

Results

CITP levels were significantly associated with MLHFQ scores both at baseline (r = 0.231, P < 0.001) and at 6 months follow-up (r = 0.145, P = 0.044). CITP levels remained significantly associated with MLHFQ score in multivariable linear regression analysis. Higher CITP levels were observed with higher MLHFQ scores (poor HRQOL) both at baseline (P = 0.001) and at 6 months (P = 0.041). Unadjusted analysis demonstrated a significant relationship between increasing CITP levels during 6 months follow-up and worsening HRQOL (r = 0.204, P = 0.001). The aforementioned correlation remained significant in multivariable linear regression analysis.

Conclusion

Our findings show that increased CITP levels are associated with poorer HRQOL in patients with CHF. These findings are consistent with a link between a pathophysiologic mechanism, i.e., collagen metabolism and patient self-assessed health status in CHF.
vorige artikel Neighborhood foreclosures and self-rated health among breast cancer survivors
volgende artikel Validation of the EQ-5D in a general population sample in urban China
Literatuur
1.
Dickstein, K., Cohen-Solal, A., Filippatos, G., McMurray, J. J. V., Ponikowski, P., Poole-Wilson, P. A., et al. (2008). ESC Guidelines for the diagnosis, treatment of acute, chronic heart failure 2008. The task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. European Heart Journal, 29(19), 2388–2442.PubMedCrossRef
2.
Al-Kaade, S., & Hauptman, P. (2001). Health-related quality of life measurement in heart failure: Challenges for the new millennium. Journal of Cardiac Failure, 7(2), 194–201.PubMedCrossRef
3.
Carels, R. A. (2004). The association between disease severity, functional status, depression and daily quality of life in congestive heart failure patients. Quality of Life Research, 13(1), 63–72.PubMedCrossRef
4.
Vaishnava, P., & Lewis, E. F. (2007). Assessment of quality of life in severe heart failure. Current Heart Failure Reports, 4(3), 170–177.PubMedCrossRef
5.
Morgan, K., McGee, H., & Shelley, E. (2007). Quality of life assessment in heart failure interventions: A 10-year (1996–2005) review. European journal of Cardiovascular Prevention and Rehabilitation, 14(5), 589–607.PubMedCrossRef
6.
Weber, K. T., Sun, Y., Tyagi, S. C., & Cleutjens, J. P. (1994). Collagen network of the myocardium: function, structural remodelling and regulatory mechanisms. Journal of Molecular and Cellular Cardiology, 26(3), 279–292.PubMedCrossRef
7.
Lopez, B., Gonzalez, A., & Diez, J. (2010). Circulating biomarkers of collagen metabolism in cardiac diseases. Circulation, 121(14), 1645–1654.PubMedCrossRef
8.
Janicki, J. S. (1995). Collagen degradation in the heart. In M. Eghbali-Webb (Ed.), Molecular biology of collagen matrix in the heart (pp. 61–76). Austin TX: RG Landes.
9.
Sternlicht, M. D., & Werb, Z. (2001). How matrix metalloproteinases regulate cell behaviour. Annual Review of Cell and Developmental Biology, 17, 463–516.PubMedCrossRef
10.
Risteli, J., Elomaa, I., Niemi, S., Novamo, A., & Risteli, L. (1993). Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: A new serum marker of bone collagen degradation. Clinical Chemistry, 39(4), 635–640.PubMed
11.
Weber, K. T. (1997). Monitoring tissue repair and fibrosis from a distance. Circulation, 96(8), 2488–2492.PubMed
12.
Klappacher, G., Franzen, P., Haab, D., Mehrabi, M., Binder, M., Plesch, K., et al. (1995). Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. The American Journal of Cardiology, 75(14), 913–918.PubMedCrossRef
13.
Kitahara, T., Takeishi, Y., Arimoto, T., Niizeki, T., Koyama, Y., Sasaki, T., et al. (2007). Serum carboxy terminal telopeptide of type I collagen (ICTP) predicts cardiac events in chronic heart failure patients with preserved left ventricular systolic function. Circulation Journal, 71(6), 929–935.PubMedCrossRef
14.
Iraqi, W., Rossignol, P., Angioi, M., Fay, R., Nuée, J., Ketelslegers, J. M., et al. (2009). Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Circulation, 119(18), 2471–2479.PubMedCrossRef
15.
Barthelemy, O., Beygui, F., Vicaut, E., Rouanet, S., van Belle, E., Bauluc, C., et al. (2009). Relation of high concentrations of plasma carboxy-terminal telopeptide of collagen type I with outcome in acute myocardial infarction. The American Journal of Cardiology, 104(7), 904–909.PubMedCrossRef
16.
Zannad, F., Alla, F., Dousset, B., Perez, A., & Pitt, B. (2000). Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: Insights from the Randomized Aldactone Evaluation Study (RALES). Circulation, 102(22), 2700–2706.PubMed
17.
Tziakas D., Chalikias G., Stakos D., Chatzikyriakou S. V., Papazoglou D., Mitrousi K., et al. (2010). Independent and additive prognostic ability of serum carboxy-terminal telopeptide of collagen type-I in heart failure patients: A multi-marker approach with high-negative predictive value to rule out long-term adverse events. European journal of cardiovascular prevention and rehabilitation. doi:10.​1097/​HJR.​0b013e32833ace76​.
18.
Cheitlin, M. D., Alpert, J. S., Armstrong, W. F., Aurigemma, G. P., Beller, G. A., Bierman, F. Z., et al. (1997). ACC/AHA guidelines for the clinical application of echocardiography. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on Clinical Application of Echocardiography). Circulation, 95(6), 1686–1744.PubMed
19.
Feigenbaum, H., Armstrong, W. F., & Ryan, T. (2005). Evaluation of systolic and diastolic function of the left ventricle. In H. Feigenbaum (Ed.), Feigenbaum’s echocardiography (6th ed., pp. 138–179). Philadelphia: Lippincott Williams & Wilkins.
20.
Rector, T. S., & Cohn, J. N. (1992). Assessment of patient outcome with the Minnesota living with heart failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. American Heart Journal, 124(4), 1017–1025.PubMedCrossRef
21.
Rector, T. S., Kubo, S. H., & Cohn, J. N. (1993). Validity of the Minnesota living with heart failure questionnaire as a measure of therapeutic response to enalapril or placebo. The American Journal of Cardiology, 71(12), 1106–1107.PubMedCrossRef
22.
Rector, T. S., Tschumperlin, L. K., Kubo, S. H., Bank, A. J., Francis, G. S., McDonald, K. M., et al. (1995). Use of the Living with heart failure Questionnaire to ascertain patients’ perspectives on improvement in quality of life versus risk of drug-induced death. Journal of Cardiac Failure, 1(3), 201–206.PubMedCrossRef
23.
Rector T. S., Kubo S. G., & Cohn J. N. (1987). Patients’ self-assessment of the occurrence of their congestive heart failure. Part 2: Content, reliability and validity of a new measure, The Minnesota living with heart failure questionnaire. Heart Failure, 3, 198–209.
24.
Chryssanthopoulos, S., Dritsas, A., & Cokkinos, D. (2005). Activity questionnaires; a useful tool in accessing heart failure patients. International Journal of Cardiology, 105(3), 294–299.PubMedCrossRef
25.
Behlouli H., Feldman D. E., Ducharme A., Frenette M., Giannetti N., Grondin F., et al. (2009). Identifying relative cut-off scores with neural networks for interpretation of the Minnesota Living with Heart Failure questionnaire. Conference Proceedings IEEE Engineering in Medicine and Biology Society, 2009, 6242–6246.
26.
Myers, J., Zaheer, N., Quaglietti, S., Madhavan, R., Froelicher, V., Heidenreich, P., et al. (2006). Association of functional and health status measures in heart failure. Journal of Cardiac Failure, 12(6), 439–445.PubMedCrossRef
27.
Flynn, K. E., Lin, L., Ellis, S. J., Russell, S. D., Spertus, J. A., Whellan, D. J., et al. (2009). Outcomes, health policy, and managed care: Relationships between patient-reported outcome measures and clinical measures in outpatients with heart failure. The American Heart Journal, 158(Suppl 4), S64–S71.CrossRef
28.
Palhares, L. C., Gallani, M. C., Gemignani, T., Matos-Souza, J. R., Ubaid-Girioli, S., Moreno, H., Jr, et al. (2010). Quality of life, dyspnea and ventricular function in patients with hypertension. Journal of Advanced Nursing, 66(10), 2287–2296.PubMedCrossRef
29.
Carson, P., Tam, S. W., Chali, J. K., Archambault, W. T., Taylor, C. A., Cohn, J. N., et al. (2009). Relationship of quality of life scores with baseline characteristics and outcomes in the African-American heart failure trial. Journal Cardiac Failure, 15(10), 835–842.CrossRef
30.
Packer, M. (1995). Evolution of the neurohormonal hypothesis to explain the progression of chronic heart failure. European Heart Journal, 16(Suppl F), 4–6.PubMed
31.
Chatzikyriakou, S. V., Tziakas, D. N., Chalikias, G. K., Stakos, D. A., Thomaidi, A. K., Mitrousi, K., et al. (2008). Serum levels of collagen type-I degradation markers are associated with vascular stiffness in chronic heart failure patients. European Journal of Heart Failure, 10(12), 1181–1185.PubMedCrossRef
32.
Adamopoulos, S., Parissis, J., & Kremastinos, D. (2001). A glossary of circulating cytokines in chronic heart failure. European Journal of Heart Failure, 3(5), 517–526.PubMedCrossRef
33.
Kop, W. J., Kuhl, E. A., Barasch, E., Jenny, N. S., Gottlieb, S. S., & Gottdiener, J. S. (2010). Association between depressive symptoms and fibrosis markers: The Cardiovascular Health Study. Brain, Behavior, and Immunity, 24(2), 229–235.PubMedCrossRef
34.
Stakos, D. A., Tziakas, D. N., Chalikias, G. K., Mitrousi, K., Tsigalou, C., & Boudoulas, H. (2010). Associations between collagen synthesis and degradation and aortic function in arterial hypertension. American Journal of Hypertension, 23(5), 488–494.PubMedCrossRef
35.
Jugdutt, B. I. (2003). Ventricular remodeling after infarction and the extracellular collagen matrix. When is enough enough ? Circulation, 108(11), 1395–1403.PubMedCrossRef
36.
Yamamoto, K., Masuyama, T., Sakata, Y., Nishikawa, N., Mano, T., Yoshida, J., et al. (2002). Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart. Cardiovascular Research, 55(1), 76–82.PubMedCrossRef
37.
Lindsay, M., Maxwell, P., & Dunn, F. G. (2002). TIMP-1: A marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension, 40(2), 136–141.PubMedCrossRef
38.
Spertus, J., Peterson, E., Conard, M. W., Heidenreich, P. A., Krumholz, H. M., Jones, P., et al. (2005). Monitoring clinical changes in patients with heart failure: A comparison of methods. American Heart Journal, 150(4), 707–715.PubMedCrossRef
39.
Lewis, E. F., Johnson, P. A., Johnson, W., Collins, C., Griffin, L., & Stevenson, L. W. (2001). Preferences for quality of life or survival expressed by patients with heart failure. Journal of Heart Lung Transplantation, 20(9), 1016–1024.CrossRef
40.
Leidy, N. K., Rentz, A. M., & Zyczynski, T. M. (1999). Evaluating health-related quality-of-life outcomes in patients with congestive heart failure: a review of recent randomised controlled trials. Pharmacoeconomics, 15(1), 19–46.PubMedCrossRef
41.
Anand, I. S., Florea, V. G., & Fisher, L. (2002). Surrogate end points in heart failure. Journal of the American College of Cardiology, 39(9), 1414–1421.PubMedCrossRef
42.
Rodríguez-Artalejo, F., Guallar-Castillón, P., Pascual, C. R., Otero, C. M., Montes, A. O., García, A. N., et al. (2005). Health-related quality of life as a predictor of hospital readmission and death among patients with heart failure. Archives of Internal Medicine, 165(11), 1274–1279.PubMedCrossRef
43.
Moser, D. K., Yamokoski, L., Sun, J. L., Conway, G. A., Hartman, K. A., Graziano, J. A., et al. (2009). Improvement in health-related quality of life after hospitalization predicts event-free survival in patients with advanced heart failure. Journal Cardiac Failure, 15(9), 763–769.CrossRef
44.
Pfisterer, M., Buser, P., Rickli, H., Gutmman, M., Erne, P., Rickenbacher, P., et al. (2009). BNP-guided vs symptom-guided heart failure therapy the trial of intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF) randomized trial. The Journal of the American Medical Association, 301(4), 383–392.CrossRef
Metagegevens
Titel
Circulating levels of a biomarker of collagen metabolism are associated with health-related quality of life in patients with chronic heart failure
Auteurs
Sofia V. Chatzikyriakou
Dimitrios N. Tziakas
Georgios K. Chalikias
Dimitrios Stakos
Dimitrios Papazoglou
Asimina Lantzouraki
Adina Thomaidi
Harisios Boudoulas
Stavros Konstantinides
Publicatiedatum
01-02-2012
Uitgeverij
Springer Netherlands
Gepubliceerd in
Quality of Life Research / Uitgave 1/2012
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-011-9932-5

Andere artikelen Uitgave 1/2012

Quality of Life Research 1/2012 Naar de uitgave

Brief Communication

The WHO quality of life (WHOQOL) questionnaire: Spanish development and validation studies

Brief Communication

Impacts of recurrent aphthous stomatitis on quality of life of 12- and 15-year-old Thai children

OriginalPaper

Mothers of infants with congenital heart defects: well-being from pregnancy through the child’s first six months

OriginalPaper

Rasch analysis of the Patient and Observer Scar Assessment Scale (POSAS) in burn scars

OriginalPaper

Measures of relative importance for health-related quality of life

Brief Communication

Quality of life of adolescents with autism spectrum disorders: concordance among adolescents’ self-reports, parents’ reports, and parents’ proxy reports